文献速递糖尿病

射血分数保留的心力衰竭患者中糖尿病及微血管并发症的预后意义

The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction.
PubMed 文献 · Diabetes Care · 2017-10-19

本研究基于TOPCAT试验的3385例HFpEF患者,分析糖尿病及微血管并发症的预后意义。结果显示,合并微血管并发症的糖尿病患者住院、心衰住院、死亡及心血管死亡风险均高于无微血管并发症者,且风险随糖尿病及微血管并发症状态呈递增趋势。

要点

  • 在HFpEF患者中,糖尿病与不良心血管结局相关,且风险随微血管并发症的存在而升高。
  • 糖尿病无微血管并发症者住院风险HR 1.18,有微血管并发症者HR 1.54,趋势P<0.001。
  • 既往因心衰住院者中,糖尿病合并微血管并发症者再住院风险HR 1.78。

核心结论

  • 糖尿病与HFpEF患者的不良心血管结局相关,且糖尿病患者的固有风险因微血管并发症的存在而异。

研究设计与样本

  • 研究纳入TOPCAT试验中3385例HFpEF患者,平均年龄69±9.6岁,49%男性,89%白人;糖尿病及微血管并发症通过自我报告病史和病历审查确定。

主要发现

  • 1109例(32%)受试者有糖尿病,其中352例(32%)至少有一种微血管并发症。
  • 与无糖尿病者相比,糖尿病无微血管并发症者住院风险HR 1.18(95%CI 1.01,1.37),糖尿病合并微血管并发症者HR 1.54(95%CI 1.25,1.89),趋势P<0.001。
  • 与无糖尿病者相比,糖尿病无微血管并发症者心衰住院风险HR 1.51(95%CI 1.14,1.99),糖尿病合并微血管并发症者HR 1.97(95%CI 1.38,2.80),趋势P<0.001。
  • 与无糖尿病者相比,糖尿病无微血管并发症者死亡风险HR 1.35(95%CI 1.04,1.75),糖尿病合并微血管并发症者HR 1.73(95%CI 1.22,2.45),趋势P=0.0017。
  • 与无糖尿病者相比,糖尿病无微血管并发症者心血管死亡风险HR 1.34(95%CI 0.96,1.86),糖尿病合并微血管并发症者HR 1.70(95%CI 1.09,2.65),趋势P=0.018。

临床怎么用

  • 在HFpEF患者中,应评估糖尿病及微血管并发症以识别不良心血管结局高风险者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study examined the prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction (HFpEF). RESEARCH DESIGN AND METHODS: This analysis included 3,385 patients (mean age 69 ± 9.6 years; 49% male; 89% white) with HFpEF from the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT). Diabetes and microvascular complications were ascertained by self-reported history and medical record review. Microvascular complications included neuropathy, nephropathy, and retinopathy. Outcomes included hospitalization, hospitalization for heart failure, death, and cardiovascular death. Cox regression was used to examine the risk of each outcome associated with diabetes and microvascular complications. RESULTS: Of the 1,109 subjects (32%) with diabetes, 352 (32%) had at least one microvascular complication. Patients with diabetes and microvascular complications had an increased risk for hospitalization (no diabetes: referent; diabetes + no microvascular complication: hazard ratio [HR] 1.18, 95% CI 1.01, 1.37; diabetes + microvascular complications: HR 1.54, 95% CI 1.25, 1.89; P-trend <0.001), hospitalization for heart failure (no diabetes: referent; diabetes + no microvascular complication: HR 1.51, 95% CI 1.14, 1.99; diabetes + microvascular complications: HR 1.97, 95% CI 1.38, 2.80; P-trend <0.001), death (no diabetes: referent; diabetes + no microvascular complication: HR 1.35, 95% CI 1.04, 1.75; diabetes + microvascular complications: HR 1.73, 95% CI 1.22, 2.45; P-trend = 0.0017), and cardiovascular death (no diabetes: referent; diabetes + no microvascular complication: HR 1.34, 95% CI 0.96, 1.86; diabetes + microvascular complications: HR 1.70, 95% CI 1.09, 2.65; P-trend = 0.018). When the analysis was limited to participants who reported prior hospitalization for heart failure (n = 2,449), a higher risk of rehospitalization for heart failure was observed across diabetes categories (no diabetes: referent; diabetes + no microvascular complication: HR 1.40, 95% CI 1.01, 1.96; diabetes + microvascular complications: HR 1.78, 95% CI 1.18, 2.70; P-trend = 0.0036). CONCLUSIONS: Diabetes is associated with adverse cardiovascular outcomes in HFpEF, and the inherent risk of adverse outcomes in HFpEF patients with diabetes varies by the presence of microvascular complications.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Sandesara PB, O'Neal WT, Kelli HM, et al. The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction. Diabetes Care. 2017. PMID: 29051160. doi:10.2337/dc17-0755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。